Merck & Co’s Keytruda gets new colorectal cancer use after month-long FDA reviewIt’s barely a month since Merck & Co unveiled trial results showing that cancer immunotherapy Keytruda (pembrolizumab) works in colorectal Share XMerck & Co’s Keytruda gets new colorectal cancer use after month-long FDA reviewhttps://pharmaphorum.com/news/merck-cos-keytruda-gets-new-colorectal-cancer-use-after-month-long-fda-review/
Intercept CEO lays into FDA after NASH drug rejectionIntercept Pharmaceuticals has accused the FDA of moving the goalposts during its review of a potential blockbuster drug for the fatty Share XIntercept CEO lays into FDA after NASH drug rejectionhttps://pharmaphorum.com/news/intercept-ceo-lays-into-fda-after-nash-drug-rejection/
Takeda to make $200m loss after Novartis’ dry-eye drug hits trouble in EuropeNovartis’ decision to withdraw a European filing for its dry-eye drug Xiidra is to have a knock-on effect on Takeda, causing Share XTakeda to make $200m loss after Novartis’ dry-eye drug hits trouble in Europehttps://pharmaphorum.com/news/takeda-to-make-200m-loss-after-novartis-dry-eye-drug-hits-trouble-in-europe/
FDA approves Akili’s video game ADHD therapyThe FDA has approved the first video game-based treatment for attention deficit hyperactivity disorder (ADHD), from Akili. Called EndeavorRx, Share XFDA approves Akili’s video game ADHD therapyhttps://pharmaphorum.com/news/fda-approves-akilis-video-game-adhd-therapy/
UK stops recruitment to hydroxychloroquine COVID-19 trialsThe UK’s drugs regulator has suspended recruitment to COVID-19 trials involving the drug hydroxychloroquine, saying that a review Share XUK stops recruitment to hydroxychloroquine COVID-19 trialshttps://pharmaphorum.com/news/uk-stops-recruitment-to-hydroxychloroquine-covid-19-trials/
FDA defies Trump and revokes emergency authorisation for hydroxychloroquineThe FDA has revoked its Emergency Use Authorization for hydroxychloroquine as a treatment for COVID-19, drawing the ire of president Donald Share XFDA defies Trump and revokes emergency authorisation for hydroxychloroquinehttps://pharmaphorum.com/news/fda-defies-trump-and-revokes-emergency-authorisation-for-hydroxychloroquine/
UK okays early access to Gilead’s remdesivir in seriously ill COVID-19 patientsThe UK’s drugs regulator has said that there is enough evidence to support the use of Gilead’s COVID-19 Share XUK okays early access to Gilead’s remdesivir in seriously ill COVID-19 patientshttps://pharmaphorum.com/news/uk-okays-early-access-to-gileads-remdesivir-in-seriously-ill-covid-19-patients/
Japan approves Gilead’s COVID-19 drug remdesivirJapan’s regulator has quickly approved Gilead’s remdesivir for patients with severe COVID-19, after the FDA allowed its use as Share XJapan approves Gilead’s COVID-19 drug remdesivirhttps://pharmaphorum.com/news/japan-approves-gileads-covid-19-drug-remdesivir/
EU regulators warn over safety of Trump’s favourite COVID drugsAs the search for therapies for COVID-19 continues, European regulators have urged caution over the cardiac side-effects of Share XEU regulators warn over safety of Trump’s favourite COVID drugshttps://pharmaphorum.com/news/eu-regulators-warn-over-safety-of-trumps-favourite-covid-drug/
